

# Correction of a pathogenic gene mutation in human embryos

Hong Ma<sup>1\*</sup>, Nuria Marti-Gutierrez<sup>1\*</sup>, Sang-Wook Park<sup>2\*</sup>, Jun Wu<sup>3\*</sup>, Yeonmi Lee<sup>1</sup>, Keiichiro Suzuki<sup>3</sup>, Amy Koski<sup>1</sup>, Dongmei Ji<sup>1</sup>, Tomonari Hayama<sup>1</sup>, Riffat Ahmed<sup>1</sup>, Hayley Darby<sup>1</sup>, Crystal Van Dyken<sup>1</sup>, Ying Li<sup>1</sup>, Eunju Kang<sup>1</sup>, A.-Reum Park<sup>2</sup>, Daesik Kim<sup>4</sup>, Sang-Tae Kim<sup>2</sup>, Jianhui Gong<sup>5,6,7,8</sup>, Ying Gu<sup>5,6,7</sup>, Xun Xu<sup>5,6,7</sup>, David Battaglia<sup>1,9</sup>, Sacha A. Krieg<sup>9</sup>, David M. Lee<sup>9</sup>, Diana H. Wu<sup>9</sup>, Don P. Wolf<sup>1</sup>, Stephen B. Heitner<sup>10</sup>, Juan Carlos Izpisua Belmonte<sup>3§</sup>, Paula Amato<sup>1,9§</sup>, Jin-Soo Kim<sup>2,4§</sup>, Sanjiv Kaul<sup>10§</sup> & Shoukhrat Mitalipov<sup>1,10§</sup>

**Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous *MYBPC3* mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type *MYBPC3* gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.**

More than 10,000 monogenic inherited disorders have been identified, affecting millions of people worldwide. Among these are autosomal dominant mutations, where inheritance of a single copy of a defective gene can result in clinical symptoms. Genes in which dominant mutations manifest as late-onset adult disorders include *BRCA1* and *BRCA2*, which are associated with a high risk of breast and ovarian cancers<sup>1</sup>, and *MYBPC3*, mutation of which causes hypertrophic cardiomyopathy (HCM)<sup>2</sup>. Because of their delayed manifestation, these mutations escape natural selection and are often transmitted to the next generation. Consequently, the frequency of some of these founder mutations in particular human populations is very high. For example, the *MYBPC3* mutation is found at frequencies ranging from 2% to 8%<sup>3</sup> in major Indian populations, and the estimated frequency of both *BRCA1* and *BRCA2* mutations among Ashkenazi Jews exceeds 2%<sup>4</sup>.

HCM is a myocardial disease characterized by left ventricular hypertrophy, myofibrillar disarray and myocardial stiffness; it has an estimated prevalence of 1:500 in adults<sup>5</sup> and manifests clinically with heart failure. HCM is the commonest cause of sudden death in otherwise healthy young athletes. HCM, while not a uniformly fatal condition, has a tremendous impact on the lives of individuals, including physiological (heart failure and arrhythmias), psychological (limited activity and fear of sudden death), and genealogical concerns. *MYBPC3* mutations account for approximately 40% of all genetic defects causing HCM and are also responsible for a large fraction of other inherited cardiomyopathies, including dilated cardiomyopathy and left ventricular non-compaction<sup>6</sup>. *MYBPC3* encodes the thick filament-associated cardiac myosin-binding protein C (cMyBP-C), a signalling node in cardiac

myocytes that contributes to the maintenance of sarcomeric structure and regulation of both contraction and relaxation<sup>2</sup>.

Current treatment options for HCM provide mostly symptomatic relief without addressing the genetic cause of the disease. Thus, the development of novel strategies to prevent germline transmission of founder mutations is desirable. One approach for preventing second-generation transmission is preimplantation genetic diagnosis (PGD) followed by selection of non-mutant embryos for transfer in the context of an *in vitro* fertilization (IVF) cycle. When only one parent carries a heterozygous mutation, 50% of the embryos should be mutation-free and available for transfer, while the remaining carrier embryos are discarded. Gene correction would rescue mutant embryos, increase the number of embryos available for transfer and ultimately improve pregnancy rates.

Recent developments in precise genome-editing techniques and their successful applications in animal models have provided an option for correcting human germline mutations. In particular, CRISPR-Cas9 is a versatile tool for recognizing specific genomic sequences and inducing DSBs<sup>7-10</sup>. DSBs are then resolved by endogenous DNA repair mechanisms, preferentially using a non-homologous end-joining (NHEJ) pathway. Obviously, NHEJ is inappropriate for gene correction applications because it introduces additional mutations in the form of insertions or deletions at the DSB site, commonly referred to as indels. In some cases, however, targeted cells activate an alternative DNA repair pathway called homology-directed repair (HDR) that rebuilds the DSB site using the non-mutant homologous chromosome or a supplied exogenous DNA molecule as a template, leading to correction of the

<sup>1</sup>Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University, 3303 Southwest, Bond Avenue, Portland, Oregon 97239, USA. <sup>2</sup>Center for Genome Engineering, Institute for Basic Science, 70, Yuseong-daero 1689-gil, Yuseong-gu, Daejeon, 34047, Republic of Korea. <sup>3</sup>Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, USA. <sup>4</sup>Department of Chemistry, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul, 151-747, Republic of Korea. <sup>5</sup>BGI-Shenzhen, Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China. <sup>6</sup>China National GeneBank, BGI-Shenzhen, Jinsha Road, Dapeng District, Shenzhen, 518210, China. <sup>7</sup>BGI-Qingdao, 2877 Tuanjie Road, Sino-German Ecopark, Qingdao, 266000, China. <sup>8</sup>Shenzhen Engineering Laboratory for Innovative Molecular Diagnostics, BGI-Shenzhen, Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China. <sup>9</sup>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Oregon Health & Science University, 3303 Southwest, Bond Avenue, Portland, Oregon 97239, USA. <sup>10</sup>Knight Cardiovascular Institute, Oregon Health & Science University, 3181 Southwest, Sam Jackson Park Road, Portland, Oregon 97239, USA.

\*These authors contributed equally to this work.

§These authors jointly supervised this work.

mutant allele<sup>11,12</sup>. At present, CRISPR–Cas9 is predominantly used to introduce mutations and in the generation of gene knockouts using intrinsic NHEJ. Because HDR efficiency is relatively low<sup>8</sup>, applications of genome editing for gene therapy have been limited.


In early attempts, the introduction of genome editing constructs into one-cell embryos (zygotes), resulted in multicellular embryos or offspring with mosaic outcomes in individual cells<sup>13,14</sup>. Also, off-target mutations that could be introduced into the developing embryo remained an undesirable possibility.

We sought to investigate human gamete and embryo DNA repair mechanisms activated in response to CRISPR–Cas9-induced DSBs. In an effort to demonstrate the proof-of-principle that heterozygous gene mutations can be corrected in human gametes or early embryos, we focused on the *MYBPC3* mutation that has been implicated in HCM. Although homozygous mutations with no PGD alternative would have been most desirable for gene correction, generating homozygous human embryos for research purposes is practically impossible. Homozygous *MYBPC3* mutations in adults are extremely rare owing to the severity of the clinical symptoms and early onset of the disease. Therefore, we specifically targeted the heterozygous four-base-pair (bp) deletion in the *MYBPC3* gene in human zygotes introduced by heterozygous, carrier sperm while oocytes obtained from healthy donors provided the wild-type allele. By accurate analysis of cleaving embryos at the single-cell level, we show high targeting efficiency and specificity of preselected CRISPR–Cas9 constructs. Moreover, DSBs in the mutant paternal *MYBPC3* gene were preferentially repaired using the wild-type oocyte allele as a template, suggesting an alternative, germline-specific DNA repair response. Mechanisms responsible for mosaicism in embryos were also investigated and a proposed solution to minimize their occurrence developed—namely the co-injection of sperm and CRISPR–Cas9 components into metaphase II (MII) oocytes.

### Subject with a heterozygous *MYBPC3*<sup>ΔGAGT</sup> deletion

An adult male patient with well-documented familial HCM caused by a heterozygous dominant 4-bp GAGT deletion (g.9836\_9839 del., NC\_000011.10) in exon 16 of *MYBPC3*, currently managed with an implantable cardioverter defibrillator and antiarrhythmic medications, agreed to donate skin, blood and semen samples. Skin fibroblast cultures were expanded and used to generate heterozygous patient induced pluripotent stem cells (iPSCs) as described previously<sup>15</sup>. Two single-guide RNA (sgRNA)–Cas9<sup>16–18</sup> constructs were designed to target this specific *MYBPC3*<sup>ΔGAGT</sup> deletion (Extended Data Fig. 1a, b) along with two exogenous single-stranded oligodeoxynucleotide (ssODN) templates encoding homology arms to the targeted region (Extended Data Table 1). To differentiate from the wild-type allele, two synonymous single-nucleotide substitutions were introduced into each ssODN template. In addition, ssODN-2 nucleotide substitutions provided an additional restriction enzyme (BstBI) recognition site (Extended Data Fig. 1a, b).

The efficacy and specificity of each construct were tested by transfecting patient iPSCs. Cells were electroporated together with ssODN, Cas9 and sgRNA expression plasmids and subcloned, and the targeted region for each clone was analysed by sequencing (Extended Data Fig. 1c). Of 61 iPSC clones transfected with CRISPR–Cas9-1, 44 (72.1%) were not targeted, as evidenced by the presence of both intact wild-type and intact mutant alleles. Among targeted clones, 10 of 17 (58.8%) were repaired by NHEJ and contained various indels adjacent to the mutation site (Extended Data Fig. 1d, e and Supplementary Table 1). The remaining seven clones were repaired by HDR using ssODN-1 as judged by the presence of the marker nucleotide substitutions. Thus, the total targeting efficiency for CRISPR–Cas9-1 was 27.9% (17/61). Among the targeted clones, only 41.2% (7/17) were repaired by HDR (Extended Data Fig. 1e). The targeting efficiency with CRISPR–Cas9-2 was 13.1% (23/175) and the HDR was considerably lower at 13% (3/23). Of note, among the three HDR-repaired iPSC clones, two were repaired using the ssODN-2 template while the third clone contained intact wild-type sequences in both alleles (Extended Data



**Figure 1 | Gene correction in S-phase-injected human embryos.**

Schematic of *MYBPC3*<sup>ΔGAGT</sup> gene targeting by injection of CRISPR–Cas9 into human zygotes at the S-phase of the cell cycle. MII oocytes were fertilized by sperm from a heterozygous patient with equal numbers of mutant and wild-type (WT) spermatozoa. CRISPR–Cas9 was then injected into one-cell zygotes. Embryos at the 4–8-cell stage were collected for genetic analysis. Injection during S-phase resulted in mosaic embryos consisting of non-targeted mutant, targeted NHEJ-repaired and targeted HDR-repaired blastomeres.

Fig. 1d, e and Supplementary Table 1), indicating HDR using the wild-type allele.


The wild-type allele in all iPSC clones analysed remained intact, demonstrating high fidelity of sgRNAs.

We also directly compared CRISPR–Cas9-1 and CRISPR–Cas9-2 in patient iPSCs transfected with preassembled Cas9 ribonucleoproteins (RNPs). Targeted deep sequencing demonstrated that CRISPR–Cas9-1 had higher HDR efficiency (Extended Data Fig. 1f). On-target mutations were not detected in wild-type embryonic stem (ES) cells (H9) carrying both wild-type *MYBPC3* alleles, demonstrating high specificity of CRISPR–Cas9-1. On the basis of these outcomes, we selected CRISPR–Cas9-1 (hereafter referred to as CRISPR–Cas9), with higher efficiency of HDR-based gene correction, for subsequent studies.

### HDR efficiency in heterozygous *MYBPC3*<sup>ΔGAGT</sup> zygotes

We next evaluated targeting outcomes in human zygotes produced by fertilizing healthy donor oocytes with sperm from the patient heterozygous for the *MYBPC3* mutation. As direct introduction of Cas9 protein is more efficient than using a plasmid<sup>9,19</sup>, recombinant Cas9 protein microinjection was adopted, injecting a mixture of sgRNA, Cas9 protein and ssODN DNA into the cytoplasm of pronuclear stage zygotes 18 h after fertilization. Injected zygotes and intact controls were cultured for 3 days before each embryonic blastomere was isolated and individually analysed by sequencing (Fig. 1). Cytoplasmic microinjection of CRISPR–Cas9 was confirmed visually (Supplementary Video 1) and shown to be efficient with a 97.1% (68/70) survival rate after injection and development rates comparable to controls (Extended Data Table 2).

Sequencing of 83 individual blastomeres collected from 19 control embryos revealed that 9 (47.4%) were homozygous wild type (*MYBPC3*<sup>WT/WT</sup>) and 10 (52.6%) were heterozygous, carrying the wild-type maternal and mutant paternal alleles (*MYBPC3*<sup>WT/ΔGAGT</sup>) (Fig. 2a and Supplementary Table 2). This distribution was expected and confirms that the heterozygous patient sperm sample contained equal numbers of wild-type and mutant spermatozoa with similar motility and fertilization efficiency.



**Figure 2 | Gene targeting and HDR efficiency in S-phase-injected human embryos.** **a**, Gene targeting efficiency in zygote, S-phase-injected embryos. **b**, Blastomere genotyping outcomes in mosaic embryos. **c**, Various blastomere genotypes in mosaic embryos. **d**, Overall targeting and HDR efficiency in S-phase-injected embryos. **e**, Targeting efficiency in patient iPSCs and S-phase-injected embryos. **f**, Yield of WT/WT embryos in control ( $n = 19$ ) and S-phase-injected ( $n = 54$ ) embryos. For source data, see Supplementary Tables 2 and 3.

Among 54 CRISPR–Cas9-injected embryos, 36 (66.7%) were uniformly homozygous for the wild-type allele with each blastomere containing  $MYBPC3^{WT/WT}$ , while 18 (33.3%) were uniform or mosaic heterozygous (Fig. 2a and Supplementary Table 3). In this group of 18, 5 embryos were uniformly heterozygous with each blastomere containing the intact wild-type and intact mutant allele ( $MYBPC3^{WT/\Delta GAGT}$ ) and 13 were mosaic, each containing blastomeres carrying more than one genotype (Fig. 2a and Supplementary Table 3). Each mosaic embryo contained at least one heterozygous blastomere with wild-type and either the intact  $\Delta GAGT$  deletion or the  $\Delta GAGT$  deletion plus additional indels, suggesting that these embryos originated from heterozygous ( $MYBPC3^{WT/\Delta GAGT}$ ) zygotes after fertilization by mutant sperm (Fig. 2b and Extended Data Table 3). Remarkably, the majority of the remaining sister blastomeres in eight mosaic embryos (numbers 1, 2, 4, 6, 7, 10, 11 and 12 in Fig. 2b) were homozygous for the wild-type allele ( $MYBPC3^{WT/WT}$ ). Overall, 52.2% (35/67) of individual blastomeres within mosaic embryos were homozygous  $MYBPC3^{WT/WT}$  (Fig. 2c and Supplementary Table 3). As these embryos originated from  $MYBPC3^{WT/\Delta GAGT}$  zygotes, individual blastomeres are likely to have repaired the  $MYBPC3^{\Delta GAGT}$  deletion by HDR using the maternal wild-type allele as a template instead of the injected ssODNs. This conclusion was corroborated by the observation that correction occurred in blastomeres of mosaic embryos not injected with ssODNs (Fig. 2b). Among the other genotypes, four mosaic embryos (numbers 5, 8, 10 and 13 in Fig. 2b) contained blastomeres with an intact, mutant allele ( $MYBPC3^{WT/\Delta GAGT}$ ), albeit with most (29.9%) also containing additional small deletions (1–20 bp length,  $n = 16$ ) or insertions (1 bp,  $n = 3$ ) adjacent to the DSB site ( $MYBPC3^{WT/\Delta GAGT-indel}$ ), characteristic of NHEJ. One blastomere carried a 10-bp deletion and a 5-bp insertion (Extended Data Table 3 and Supplementary

Table 3) and mosaic embryo #9 displayed four various NHEJ genotypes in its blastomeres, suggesting that targeting and NHEJ repair had occurred independently multiple times after the first zygotic division.

The overall targeting efficiency in human embryos was 72.2% (13/18), much higher than in iPSCs exposed to the same construct at 27.9% (17/61) (Fig. 2d, e), probably owing to more efficient delivery of the CRISPR–Cas9 constructs by zygote microinjection as compared to transfection in iPSCs. Even more remarkably, the majority of targeted blastomeres (63.6%, 35/55) resolved the DSBs by HDR using the wild-type allele, also markedly different from what was seen in iPSCs (Fig. 2d and Extended Data Fig. 2a). We did not find any evidence of HDR using exogenous ssODN, suggesting that HDR is guided exclusively by the wild-type maternal allele.


As HDR calculations are based on mosaic embryos only, it is probable that some targeted heterozygous ( $MYBPC3^{WT/\Delta GAGT}$ ) zygotes repaired the mutant allele in all blastomeres using the wild-type template ( $MYBPC3^{WT/WT}$ ). These HDR-repaired, uniform embryos would be indistinguishable from their wild-type homozygous counterparts, thereby increasing the portion of  $MYBPC3^{WT/WT}$  embryos in the CRISPR–Cas9 injected group. Indeed, 66.7% (36/54) of injected embryos were homozygous WT/WT, a substantial increase over the WT/WT yield (47.4%, 9/19) in control non-injected embryos (Fig. 2f). Similar to observations in iPSCs, the wild-type allele was intact in all human embryos, corroborating the specificity of the sgRNA.

In summary, these results clearly demonstrate that CRISPR–Cas9 gene targeting in human zygotes is exceptionally efficient and that DSBs in the mutant paternal allele were predominantly repaired through HDR. Furthermore, HDR was exclusively directed by the homologous wild-type allele present on the maternal chromosome. This outcome suggests that human embryos employ different DNA repair mechanisms than do somatic or pluripotent cells, probably reflecting evolutionary requirements for stringent control over genome fidelity in the germline.

### Targeting gametes eliminates mosaicism

Mosaicism in gene-targeted human embryos is unacceptable in clinical applications. The presence even of a single mutant blastomere within a mosaic embryo would make detection by PGD problematic; therefore, molecular mechanisms responsible for mosaicism were investigated. Analysis of targeting outcomes in the majority of mosaic, zygote-injected human embryos revealed only two different genotypes ( $MYBPC3^{WT/HDR}$  and  $MYBPC3^{WT/\Delta GAGT-indel}$ , or  $MYBPC3^{WT/HDR}$  and  $MYBPC3^{WT/\Delta GAGT}$ ; Fig. 2b and Extended Data Table 3). Embryos #5 and #9 were the exceptions, containing three or more genotypes (Extended Data Table 3). These findings suggest that CRISPR–Cas9 targeted at least two mutant sperm alleles despite injection into the zygote. There are two different possible explanations for this outcome: 1) at the time of injection, a zygote had completed the S-phase of the cell cycle with DNA replication and already produced two mutant alleles<sup>20</sup>; 2) CRISPR–Cas9 remained active, continuing to target after zygotic division.

We hypothesized that both situations could be abrogated if CRISPR–Cas9 was co-injected with sperm into the M-phase oocyte during fertilization by intracytoplasmic sperm injection (ICSI), allowing genome editing to occur when the sperm undoubtedly still contains a single mutant copy<sup>21</sup>. In addition, the extended time of exposure to MII cytoplasm could allow CRISPR–Cas9 components to degrade before DNA replication resulted in two or more mutant alleles (Fig. 3a). Therefore, CRISPR–Cas9 was mixed with the sperm suspension and co-injected into 75 MII oocytes during ICSI (Supplementary Video 1); no difference was observed in the survival, fertilization and cleavage rates between CRISPR–Cas9-injected and intact control oocytes (Extended Data Table 2). At day 3 after fertilization, embryos were disaggregated and each individual blastomere was analysed as



**Figure 3 | Gene correction in M-phase-injected human embryos.**

**a**, Schematic of *MYBPC3*<sup>ΔGAGT</sup> gene targeting in MII oocytes. CRISPR-Cas9 was co-injected with sperm into MII oocytes during ICSI. This allows genome editing to occur when a sperm contains a single mutant copy and eliminates mosaicism. **b**, Targeting efficiency in M-phase-injected embryos. **c**, Yield of WT/WT embryos in control ( $n = 19$ ) and

described above for S-phase-injected zygotes. Blastomeres from 16 of 58 (27.6%) M-phase-injected embryos were uniformly heterozygous, carrying an intact wild-type maternal allele along with NHEJ-repaired mutant paternal sequences carrying various indels (*MYBPC3*<sup>WT/ΔGAGT-indel</sup>) (Fig. 3b and Supplementary Table 4). The remaining 42 (72.4%) were *MYBPC3*<sup>WT/WT</sup>. Of these, the vast majority (41/42) were uniformly homozygous embryos consisting of blastomeres carrying indistinguishable *MYBPC3*<sup>WT/WT</sup> alleles. Interestingly, the remaining embryo (M2-WT42) contained four blastomeres with *MYBPC3*<sup>WT/WT</sup> but HDR-repaired with ssODN, while the other three sister blastomeres were *MYBPC3*<sup>WT/WT</sup>, suggesting HDR using the maternal wild-type allele (Supplementary Table 4). No heterozygous blastomeres with intact mutant alleles (*MYBPC3*<sup>WT/ΔGAGT</sup>) were detected, indicating 100% targeting efficiency in the M-phase-injected group compared to 72.2% efficiency in the S-phase-injected zygotes (Fig. 2d and Fig. 3b). More importantly, all sister blastomeres in all but one embryo carried identical genotypes, indicating a marked reduction in mosaicism in M-phase-injected embryos. The only mosaic embryo had all blastomeres repaired by HDR (either wild-type or ssODN as a template). Thus, this embryo, with every blastomere carrying repaired *MYBPC3*<sup>WT/WT</sup>, would be eligible for transfer.

The yield of *MYBPC3*<sup>WT/WT</sup> embryos (72.4%, 42/58) in the M-phase-injected group was significantly higher than in untreated controls (47.4%, 9/19) (Fig. 3c,  $P < 0.05$ ), reflecting enhanced targeted correction of the mutant paternal alleles with DSB repair using the wild-type homologous chromosome as a template even in the presence of ssODNs (Fig. 3d). To rule out the possibility that the observed increase in WT/WT embryos in CRISPR-Cas9-injected zygotes and oocytes was due to allele drop-out during PCR and Sanger sequencing, we validated genotypes by independent on-target deep sequencing (Extended Data Fig. 2b). The estimated HDR-based repair and increase in WT/WT embryos for the S-phase-injected and M-phase-injected groups were 16.7% (9/54) and 22.4% (13/58), respectively (Fig. 3e). In summary, delivery of CRISPR-Cas9 into MII oocytes provides more efficient targeting than injection into zygotes while eliminating mosaicism.

M-phase-injected ( $n = 58$ ) embryos. Significance established with one-tailed Fisher's test. **d**, HDR outcomes with or without ssODN. **e**, HDR efficiencies in S- and M-phase-injected embryos compared to controls. In the S-phase-injected group, each mosaic embryo (green) contained blastomeres with different genotypes. For source data, see Supplementary Table 4.


## Development and cytogenetics of repaired embryos

To examine the effect of gene correction on preimplantation development, we cultured CRISPR-Cas9-injected embryos to blastocysts. Similar to intact controls, 72.7% (16/22) of M-phase-injected embryos developed to the eight-cell stage and 50.0% (11/22) progressed to blastocysts (Student's  $t$ -test,  $P > 0.05$ ) (Fig. 4a, b). In an effort to provide additional insights into the developmental competence of gene-corrected blastocysts, and to obtain sufficient cellular material for detailed cytogenetic studies, we established six ES cell lines from CRISPR-Cas9-injected blastocysts and one from controls. On-target analysis revealed that four CRISPR-Cas9-treated ES cell lines (ES-WT1, ES-WT2, ES-WT3 and ES-WT4) and one control cell line (ES-C1) were *MYBPC3*<sup>WT/WT</sup> whereas the remaining two CRISPR-Cas9-injected cell lines (ES-Mut1 and ES-Mut2) were *MYBPC3*<sup>WT/ΔGAGT-indel</sup> (Extended Data Fig. 3a). These results corroborate the exceptionally high targeting efficiency of CRISPR-Cas9 in M-phase-injected human embryos.

Cytogenetic G-banding analysis revealed that ES-WT1, ES-WT4, ES-Mut1 and ES-Mut2 carried normal diploid karyotypes with no evidence of detectable numerical or structural chromosomal rearrangements (Extended Data Fig. 3a). Notably, ES-WT2, ES-WT3 and the control line ES-C1 exhibited a pericentric inversion on chromosome 10 (Extended Data Fig. 3a-d). As both treated and control ES cells showed this chromosomal rearrangement, we reasoned that it was contributed by the sperm and could be inherited. Indeed, analysis of the patient's skin fibroblast-derived iPSCs showed the same inversion, indicating that this inversion was balanced. In summary, CRISPR-Cas9-treated human embryos displayed normal development to blastocysts and ES cells without cytogenetic abnormalities.

## Off-target consequences in repaired human embryos

Apart from the overall targeting and HDR efficacy and mosaicism, one safety concern regarding clinical application of gene correction in human embryos is that CRISPR-Cas9 can induce undesirable off-target mutations at genome regions that are highly homologous to the targeted sequence<sup>22-24</sup>. Therefore, we conducted a comprehensive, whole-genome



**Figure 4 | Preimplantation development of CRISPR–Cas9-injected embryos.** **a**, Fertilization of CRISPR–Cas9-treated ( $n = 22$ ) and control ( $n = 10$ ) MII oocytes and their subsequent development to the eight-cell and blastocyst stage embryos. Number of oocytes/embryos/blastocysts

shown in bars; percentage shown above bars. Error bars are mean  $\pm$  s.e.m. Significance established using Student's *t*-test. **b**, Representative images showing normal morphology of CRISPR–Cas9-injected pronuclear stage zygotes, eight-cell embryos and blastocysts.

sequencing (WGS) analysis of the patient's genomic DNA by digested genome sequencing (Digenome-seq)<sup>25,26</sup>. Potential off-target sequences were identified by digestion of iPSC-derived, cell-free genomic DNA with CRISPR–Cas9 followed by WGS. Sequencing reads of CRISPR–Cas9-digested genomic DNA are vertically aligned at on-/off-target sites in IGV viewer<sup>25,27</sup>. By contrast, undigested genomic sites are aligned in a staggered manner at those loci. In addition, improved Digenome-seq provides DNA cleavage scores for potential off-target sites based on alignment patterns of sequence reads<sup>26</sup>. Digested iPSC DNA produced uniform cleavage patterns at both on-target and potential off-target sites (Extended Data Fig. 4a, b). We identified 16 potential off-target sites with a DNA cleavage score higher than 2.5 (ref. 26) (Extended Data Fig. 5a and Extended Data Table 4). Sequencing analysis of these 16 sites with Web Logo (<http://weblogo.berkeley.edu/>) confirmed that they are indeed highly homologous to the on-target *MYBPC3* mutant allele<sup>28</sup> (Extended Data Fig. 5b). Furthermore, we identified seven additional sites with DNA cleavage scores of 0.1 or greater and with ten or fewer nucleotides mismatched in the human genome (Extended Data Table 4). Next, we sequenced and analysed all these sites in each individual blastomere from two untreated control embryos (C2 and C10 from Supplementary Table 2), two mosaic S-phase-injected embryos (Mos1 and Mos7), one uniform, non-mosaic S-phase-injected embryo (WT15 from Supplementary Table 3) and two M-phase-injected embryos (M2-WT10 and M2-Mut7 from Supplementary Table 4) (Extended Data Table 5). All on-target indels in each blastomere were corroborated and results were identical to the Sanger sequencing results. In addition, indels were not detected in any blastomeres known to be carrying either intact WT/WT or WT/Mut alleles at the target site (Extended Data Fig. 5c and Supplementary Table 5). More importantly, indels were also not detected in 23 off-target loci examined in 28 screened blastomeres (Extended Data Fig. 5d). In selected blastomeres (Extended Data Fig. 5c), we extended off-target screening by WGS. Potential off-target sites were examined by comparing genomic variants found in intact, control embryos (C2.3, C10.2) with those in CRISPR–Cas9-injected embryos (Mos1.1, W15.4, Mos7.2, M2-WT10.1, and M2-Mut7.1) (Extended Data Table 6). After filtering out annotated variants in the dbSNP database, we found 19–71 potential off-target sites with indels in each blastomere obtained from

CRISPR–Cas9-injected embryos (lanes 4 and 7 in Extended Data Table 6). All of these sites contained repeated sequences such as poly-A or poly-GT repeats (lanes 5 and 8), suggesting that indels found at these sites were caused by sequencing errors rather than Cas9-catalysed, off-target DNA cleavage. These WGS results support our Digenome-seq conclusions that gene correction did not induce any detectable off-target mutations in selected blastomeres (Extended Data Table 6).

We also investigated whether CRISPR–Cas9 targeting induced global off-target genetic variations and genome instability by performing whole-exome sequencing (WES) in CRISPR–Cas9-treated ES cells and compared the results to those of control ES cells and corresponding egg and sperm donor blood DNA. WES analysis revealed a large number of variants in all samples when compared to the hg19 reference genome (Supplementary Table 6). The majority of these variants were also present in egg or sperm donors and found in the dbSNP and 1000genomes databases. Some variants detected in ES cells showed decreased fractions matching the population hotspots, indicating the potential effect of experimental procedures, including embryo culture and ES cell derivation and culture (Extended Data Fig. 6a and Supplementary Table 6). Three treated ES cell lines and a control line (ES-Mut1, ES-WT1, ES-WT2 and ES-C1) showed similar statistics in all variant categories and were comparable to gamete donor profiles (egg donors 1 and 2, sperm donor). ES-WT3 exhibited an increase in variant numbers but this sample did not have a control sibling ES cell line for comparison (Extended Data Fig. 6b, c and Supplementary Table 6). Next, we investigated potential off-target effects in ES cells and identified a total of 685 potential off-target sites using full sensitive aligner Batmis (V3.00)<sup>29</sup> (Supplementary Table 7). Variants that were also present in the gamete donors were filtered out as inherited (Supplementary Table 8). Notably, analysis of these sites did not reveal any variants. Taken together, these Digenome-seq, WGS and WES results demonstrate high on-targeting specificity of CRISPR–Cas9 in human embryos without any off-target effects.

## Discussion

DSBs induced by genome editing are primarily resolved via error-prone NHEJ, and such repair approaches are predominantly used to generate gene knockouts in cells and organisms<sup>17,30,31</sup>. By contrast, HDR,

although occurring at a substantially lower efficiency, is necessary for gene correction, particularly when human germline gene therapy is envisioned. We show here that DSBs in human gametes and zygotes are preferentially resolved using an endogenous HDR mechanism, exclusively directed by the wild-type allele as a repair template. By contrast, HDR efficiency in iPSCs was significantly lower and primarily achieved through an exogenous DNA template. This striking difference implies that human gametes and embryos employ a different DNA damage response system, perhaps reflecting the evolutionary importance of maintaining germline genome integrity<sup>32</sup>. If, as seems likely, gametes and zygotes endure an increased number of DSBs during meiotic recombination and segregation, an efficient genome repair capacity would be critical<sup>33</sup> and unique zygotic DNA repair machinery might rely entirely on maternal oocyte factors deposited and stored during maturation since zygotes are transcriptionally silent. Recent studies suggest that oocytes might employ an ataxia-telangiectasia mutated (ATM)-mediated DNA damage signalling (DDS) pathway that regulates repair of DSBs via a homologous recombination mechanism<sup>34</sup>. Thus, Cas9-induced DNA breaks are likely to attract the existing native oocyte machinery reserved for repair of meiotic recombination-induced DSBs. On the basis of our results, it may not even be necessary to provide exogenous oligo templates for gene correction in heterozygous human embryos.

The efficiency of CRISPR–Cas9 was evaluated recently in a mouse study involving a heterozygous dominant mutation in the *Crygc* gene responsible for an inherited form of cataracts. Some HDR-repaired events used sequences from the wild-type allele from the homologous chromosome<sup>12</sup>. However, HDR via the exogenous oligo template was more frequent, with three of four pups carrying corrected *Crygc* genes with a DNA sequence from the exogenous oligo and only one from the wild-type allele. In a study involving human heterozygous embryos, HDR was exclusively directed by the exogenous DNA template with no evidence of wild-type allele-based repair<sup>35</sup>. As these results were derived from bulk DNA from whole embryos rather than individual blastomeres, it is possible that instances of HDR via the wild-type allele were overlooked.

Despite remarkable targeting efficiency and high HDR frequency, some CRISPR–Cas9-treated human embryos demonstrated NHEJ-induced indels and thus would not be suitable for transfer. Therefore, genome editing approaches must be further optimized before clinical application of germline correction can be considered. Modifications in genome editing by inhibiting NHEJ mechanisms while enhancing HDR pathways have been reported<sup>36,37</sup>. Other approaches have been focused on manipulating the cell cycle or modifying the donor ssDNA design<sup>11,30</sup>. While some of these developments significantly improved HDR outcomes in the context of cultured cells, their relevance to embryonic gene correction remains unknown. In addition, supplementary exposure of human gametes or embryos to small molecules and/or inhibitors may adversely affect embryonic development.

Nonhuman primate studies have demonstrated that CRISPR–Cas9 injection into monkey zygotes can disrupt wild-type genes, with the resultant full-term offspring carrying the mutations and associated phenotypes<sup>38,39</sup>. Similar to the outcomes seen in mice and other animals, genome-edited human preimplantation embryos and newborn monkeys display mosaic targeting genotypes in their cells and tissues, suggesting that DSBs and subsequent repair do not occur at the single mutant allele stage<sup>35,40,41</sup>. As discussed above, mosaicism in gene-corrected human embryos would be difficult to detect and would, therefore, pose serious safety issues for possible clinical applications. Modifications involving shortening the half-life of Cas9 activity reduced, but did not completely eliminate, the manifestations of mosaicism in monkey embryos<sup>41</sup>, while introduction of CRISPR–Cas9 into early-stage zygotes reduced mosaicism in mouse embryos<sup>42</sup>.

Importantly, we demonstrate that the delivery of CRISPR–Cas9 into M-phase oocytes abolished mosaicism in cleaving embryos, suggesting that gene targeting and editing efficiencies are strongly associated with

DNA synthesis and the cell cycle phase<sup>42</sup>. The choice of DSB repair using either NHEJ or HDR may be dependent on the cell cycle phase, with HDR restricted to late S and G2 phases when DNA replication is completed and sister chromatids are available as repair templates<sup>11</sup>. In particular, HDR mechanisms were downregulated at the M and early G1 phases, thus favouring NHEJ-induced genome editing<sup>43</sup>. However, we did not observe reduced HDR efficiency even when CRISPR–Cas9 was delivered into MII oocytes at the time of ICSI. One possible explanation is that the DNA repair response is different in germ cell meiotic M phase compared to mitotic M phase in cultured cells. Alternatively, the DSBs may have occurred at the M or G1 phase, while the HDR repair followed later at the S or G2 phase of the cell cycle.

Extensive reports on potential off-target DNA damage induced by CRISPR–Cas9 beyond the intended targeting region have been published. In particular, Cas9 overexpression via plasmid transfection and subsequent high enzyme concentrations increased off-site targeting<sup>9</sup>. In our studies with human oocytes and zygotes, we used purified recombinant Cas9 protein instead of plasmid, which may enhance the specificity while shortening enzymatic exposure time, thereby diminishing off-site targeting. Screening by Digenome-seq, WGS and WES did not detect any off-target mutations in multiple individual blastomeres from CRISPR–Cas9-injected human embryos or ES cells. In addition, WES demonstrated maintenance of genome stability after gene correction. CRISPR–Cas9 targeting seen in our investigation was very accurate, providing assurance regarding safety concerns.

Other issues that need to be addressed include the applicability of this gene correction approach to other heterozygous mutations in humans. It may be challenging to repair homozygous mutations in human embryos when both alleles are mutant and wild-type allele-based HDR mechanisms cannot be employed.

As indicated, PGD may be a viable option for heterozygous couples at risk of producing affected offspring. In cases when only one parent carries a heterozygous mutation, 50% of embryos should be mutant. In contrast, targeted gene correction can potentially rescue a substantial portion of mutant human embryos, thus increasing the number of embryos available for transfer.

**Online Content** Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

**Received 28 March; accepted 27 June 2017.**

**Published online 2 August 2017.**

- Antoniou, A. *et al.* Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am. J. Hum. Genet.* **72**, 1117–1130 (2003).
- Carrier, L., Mearini, G., Stathopoulou, K. & Cuello, F. Cardiac myosin-binding protein C (*MYBPC3*) in cardiac pathophysiology. *Gene* **573**, 188–197 (2015).
- Dhandapani, P. S. *et al.* A common *MYBPC3* (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. *Nat. Genet.* **41**, 187–191 (2009).
- Struwing, J. P. *et al.* The risk of cancer associated with specific mutations of *BRCA1* and *BRCA2* among Ashkenazi Jews. *N. Engl. J. Med.* **336**, 1401–1408 (1997).
- Maron, B. J. *et al.* Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. *Circulation* **92**, 785–789 (1995).
- Schlossarek, S., Mearini, G. & Carrier, L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. *J. Mol. Cell. Cardiol.* **50**, 613–620 (2011).
- Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR–Cas9 for genome engineering. *Cell* **157**, 1262–1278 (2014).
- Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826 (2013).
- Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J. S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res.* **24**, 1012–1019 (2014).
- Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).
- Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. *eLife* **3**, e04766 (2014).

12. Wu, Y. *et al.* Correction of a genetic disease in mouse via use of CRISPR-Cas9. *Cell Stem Cell* **13**, 659–662 (2013).
13. Guo, X. & Li, X. J. Targeted genome editing in primate embryos. *Cell Res.* **25**, 767–768 (2015).
14. Wang, H. *et al.* One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918 (2013).
15. Kang, E. *et al.* Age-related accumulation of somatic mitochondrial DNA mutations in adult-derived human iPSCs. *Cell Stem Cell* **18**, 625–636 (2016).
16. Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat. Biotechnol.* **31**, 230–232 (2013).
17. Kim, H. & Kim, J. S. A guide to genome engineering with programmable nucleases. *Nat. Rev. Genet.* **15**, 321–334 (2014).
18. Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–821 (2012).
19. Aida, T. *et al.* Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. *Genome Biol.* **16**, 87 (2015).
20. Capmany, G., Taylor, A., Braude, P. R. & Bolton, V. N. The timing of pronuclear formation, DNA synthesis and cleavage in the human 1-cell embryo. *Mol. Hum. Reprod.* **2**, 299–306 (1996).
21. Suzuki, T., Asami, M. & Perry, A. C. Asymmetric parental genome engineering by Cas9 during mouse meiotic exit. *Sci. Rep.* **4**, 7621 (2014).
22. Fu, Y. *et al.* High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat. Biotechnol.* **31**, 822–826 (2013).
23. Hsu, P. D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* **31**, 827–832 (2013).
24. Cho, S. W. *et al.* Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. *Genome Res.* **24**, 132–141 (2014).
25. Kim, D. *et al.* Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. *Nat. Methods* **12**, 237–243 (2015).
26. Kim, D., Kim, S., Kim, S., Park, J. & Kim, J. S. Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. *Genome Res.* **26**, 406–415 (2016).
27. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
28. Schneider, T. D. & Stephens, R. M. Sequence logos: a new way to display consensus sequences. *Nucleic Acids Res.* **18**, 6097–6100 (1990).
29. Tennakoon, C., Purbojati, R. W. & Sung, W. K. BatMis: a fast algorithm for k-mismatch mapping. *Bioinformatics* **28**, 2122–2128 (2012).
30. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. *Nat. Biotechnol.* **34**, 339–344 (2016).
31. Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. *Science* **346**, 1258096 (2014).
32. Luo, Y. *et al.* Hypersensitivity of primordial germ cells to compromised replication-associated DNA repair involves ATM-p53-p21 signaling. *PLoS Genet.* **10**, e1004471 (2014).
33. Lange, J. *et al.* The landscape of mouse meiotic double-strand break formation, processing, and repair. *Cell* **167**, 695–708 (2016).
34. Titus, S. *et al.* Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. *Sci. Transl. Med.* **5**, 172ra21 (2013).
35. Tang, L. *et al.* CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. *Mol. Genet. Genomics* **292**, 525–533 (2017).
36. Chu, V. T. *et al.* Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat. Biotechnol.* **33**, 543–548 (2015).
37. Maruyama, T. *et al.* Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol.* **33**, 538–542 (2015).
38. Niu, Y. *et al.* Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. *Cell* **156**, 836–843 (2014).
39. Kang, Y. *et al.* CRISPR/Cas9-mediated *Dax1* knockout in the monkey recapitulates human AHC-HH. *Hum. Mol. Genet.* **24**, 7255–7264 (2015).
40. Liang, P. *et al.* CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. *Protein Cell* **6**, 363–372 (2015).
41. Tu, Z. *et al.* Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos. *Sci. Rep.* **7**, 42081 (2017).
42. Hashimoto, M., Yamashita, Y. & Takemoto, T. Electroporation of Cas9 protein/sgRNA into early pronuclear zygotes generates non-mosaic mutants in the mouse. *Dev. Biol.* **418**, 1–9 (2016).
43. Orthwein, A. *et al.* Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. *Science* **344**, 189–193 (2014).

**Supplementary Information** is available in the online version of the paper.

**Acknowledgements** We acknowledge the OHSU Institutional Review Board (IRB), Innovative Research Advisory Panel (IRAP), Scientific Review Committee (SRC) and Data Safety Monitoring Committee (DSMC) for oversight and guidance on this study. We thank all study participants for tissue donations; the Women’s Health Research Unit staff, IVF laboratory staff, University Fertility Consultants and the Reproductive Endocrinology and Infertility Division in the Department of Obstetrics and Gynecology, OHSU for support and procurement of human gametes; S. Olson and Research Cytogenetics Laboratory at OHSU for cytogenetic analysis of ES cells; S. Cooper from the Wallace Division of Smiths Medical for donating ICSI and gamete manipulation micropipettes; Y. Wang, T. Wu and Y. Shen from BGI-Shenzhen for help with sample preparation, sequencing and data analyses; M. Ku from the H. A. and Mary K. Chapman Charitable Foundations Genomic Sequencing Core of the Salk Institute for next generation sequencing; and E. Aizawa and R. Hernandez-Benitez from the laboratory of JCI B for assistance. Studies conducted at OHSU were supported by OHSU institutional funds. Work in the laboratory of J.-S.K. was supported by the Institute for Basic Science (IBS-R021-D1). Work in the laboratory of J.C.I.B. was supported by the G. Harold and Leila Y. Mathers Charitable Foundation, the Moxie Foundation and the Leona M. and Harry B. Helmsley Charitable Trust. Work at BGI was supported by the Shenzhen Municipal Government of China (DRC-SZ [2016] 884).

**Author Contributions** S.M., S.K., Y.Le., N.M.-G. and H.M. conceived the study and designed the experiments. S.-W.P., J.-S.K. and K.S. designed CRISPR-Cas9 constructs. A.K., S.B.H. and S.K. coordinated recruitment of gamete donors. Y.Le. and R.A. derived patient iPSCs and S.-W.P., J.W., K.S. and J.C.I.B. tested the specificity of the CRISPR-Cas9 systems in patient iPSCs. P.A., D.B., D.M.L., S.A.K. and D.H.W. conducted ovarian stimulation and oocyte retrieval. N.M.-G., Y.Le., D.J. and T.H. performed CRISPR-Cas9 injections, fertilizations, embryo culture and blastomere isolation experiments. N.M.-G., D.J., H.D., C.V.D., Y.Li and E.K. performed DNA extraction, PCR and Sanger sequencing. S.-W.P., A.-R.P., D.K., S.-T.K. and J.-S.K. performed Digenome-seq, WGS and analyses and independently corroborated embryo on-target editing by deep sequencing. J.G., Y.G., X.X. and J.W. performed whole-exome sequencing and analyses. H.M., N.M.-G., S.-W.P., J.W., A.K., D.P.W., S.B.H., J.C.I.B., P.A., J.-S.K., S.K. and S.M. analysed the data and wrote the manuscript.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Correspondence and requests for materials should be addressed to S.M. ([mitalipo@ohsu.edu](mailto:mitalipo@ohsu.edu)), S.K. ([kauls@ohsu.edu](mailto:kauls@ohsu.edu)), J.-S.K. ([jskim01@snu.ac.kr](mailto:jskim01@snu.ac.kr)), P.A. ([amatop@ohsu.edu](mailto:amatop@ohsu.edu)) or J.C.I.B. ([belmonte@salk.edu](mailto:belmonte@salk.edu)).

**Reviewer Information** Nature thanks F. Lanner and the other anonymous reviewer(s) for their contribution to the peer review of this work.

## METHODS

**Regulations for research on human gametes and embryos.** The regulatory framework surrounding the use of human gametes and embryos for this research was based on the guidelines set by the Oregon Health & Science University (OHSU) Stem Cell Research Oversight Committee (OSCRO). In 2008, OSCRO established policy and procedural guidelines formally defining the use of human embryos and their derivatives at OHSU, informed by the National Academy of Sciences' Guidelines. These policies and guidelines permitted the procurement of gametes and embryos for research purposes, the creation of human embryos specifically for research, genetic manipulation of human gametes and embryos, creation of human embryonic stem cell lines and molecular analyses. Together, OSCRO and the OHSU Institutional Review Board (IRB) worked concurrently to review and monitor applications for research studies involving human embryos at OHSU.

Human embryo and embryonic stem cell research policies and principles at OHSU were vetted over the course of a decade informed by the NAS guidelines, and subsequently affirmed by new guidelines released in 2015 by the Hinxtion Group, the International Society for Stem Cell Research (ISSCR), and 2017 recommendations by the NAS and National Academy of Medicine joint panel on human genome editing.

As part of the review process, OHSU convened additional *ad hoc* committees to evaluate the scientific merit and ethical justification of the proposed study: the OHSU Innovative Research Advisory Panel (IRAP) and a Scientific Review Committee (SRC). Members of both committees were independent and their names were kept confidential from the research team; OHSU Research Integrity supervised all committee meetings, documentation, and formal recommendations.

**Ethical review.** While international discussions were in their infancy, the OHSU Innovative Research Advisory Panel (IRAP) Committee was tasked with deliberating ethical considerations related to using gene correction technology in human embryos for basic research at OHSU. The committee was composed of eleven members from internal and external sources: a lay member, a clinical ObGyn physician, three bioethicists, an OHSU Institutional Ethics committee member, three former OSCRO members, a clinical geneticist, and a clinician. Upon completion of the review, the IRAP recommended allowing this research "with significant oversight and continued dialogue, the use of gene correction technologies in human embryos for the purpose of answering basic science questions needed to evaluate germline gene correction prior to the use in human models," at OHSU.

**Study oversight.** The established track record of the study team to uphold strict confidentiality and regulatory requirements paved the way for full OHSU IRB study approval in 2016, contingent upon strict continuing oversight which includes: a phased scientific approach requiring evaluation of results on the safety and efficacy of germline gene correction in iPSCs before approving studies on human pre-implantation embryos; external bi-annual monitoring of all regulatory documents regarding human subjects; bi-annual Data Safety Monitoring Committee (DSMC) review; and annual continuing review by the OHSU IRB. The DSMC is required to remain active for the length of the approved IRB protocol and consists of four members: a lay member, an ethicist, a geneticist, and a reproductive endocrinologist. This committee conducts full review of all donations, the subsequent uses of these samples, and participant adverse events. The DSMC provides formal recommendations to the study team and IRB at the completion of each meeting.

**Informed consent.** The robust regulatory framework set forth by OHSU clearly specified that informed consent could be obtained only if prospective donors were made aware of the sensitive nature of the study. The consent form clearly presented the scientific rationale for the study; stating (in both the *Clinical Research Consent Summary* and the *Purpose* section of the consent form) that gene editing tools will be used on eggs, sperm, and/or embryos to evaluate the safety and efficacy of gene correction for heritable diseases. Additionally, consent form language clearly stated that genetic testing would be conducted in addition to creation of preimplantation embryos and embryonic stem cell lines for *in vitro* analyses and stored for future use. The incidental discovery of genetic information that might be important to the donors' healthcare is a possible outcome when engaging in this type of research. Informed consent documents provided the donor with the option to receive this information or not. Written informed consent was obtained before all study-related procedures on current, IRB-approved, study-specific consent forms.

**Study participants.** Healthy gamete donors were recruited locally, via print and web-based advertising. Homozygous and heterozygous adult patients with known heritable *MYBPC3* mutations were sought; however, only three adult heterozygous patients were identified by OHSU Knight Cardiovascular Institute physicians and referred to the research team, one of whom agreed to participate in the study.

**Controlled ovarian stimulation.** Research oocyte donors were evaluated before study inclusion as previously reported; standard IVF protocols and procedures for ovarian stimulation were described previously<sup>44</sup>. Oocyte donation cycles were managed by OHSU Fertility physicians. Immediately following oocyte retrieval,

recovered gametes were transferred to the research laboratory. All study-related procedures took place at the OHSU Center for Embryonic Cell and Gene Therapy. Following oocyte retrieval, cumulus-oocyte complexes (COCs) were treated with hyaluronidase to disaggregate cumulus and granulosa cells. Mature metaphase II (MII) oocytes were placed in Global Medium (LifeGlobal, IVFonline) supplemented with 10% serum substitute supplement (Global 10% medium) at 37°C in 6% CO<sub>2</sub> and covered with tissue culture oil (Sage IVE, Cooper Surgical).

**Compensation.** All research donors were compensated for their time, effort, and discomfort associated with the donation process at rates similar to those used for gamete donation for fertility purposes.

**Intracytoplasmic sperm injection (ICSI).** MII oocytes were placed into a 50- $\mu$ l micromanipulation droplet of HTF (modified human tubal fluid) with HEPES 10% medium. The droplet was covered with tissue culture oil. The dish was then mounted on the stage of an inverted microscope (Olympus IX71) equipped with a stage warmer (<http://www.tokaihit.com>) and Narishige micromanipulators. Oocytes were fertilized by ICSI using frozen and thawed sperm. Fertilization was determined approximately 18 h after ICSI by noting the presence of two pronuclei and second polar body extrusion.

**CRISPR-Cas9 injection into zygote or oocytes.** For S-phase injections, zygotes were collected 18 h after ICSI and placed in a micromanipulation drop. The CRISPR-Cas9 mixture, containing Cas9 protein (200 ng/ $\mu$ l), sgRNA (100 ng/ $\mu$ l) and ssODN (200 ng/ $\mu$ l), was then injected into the cytoplasm. Injected zygotes were cultured in Global 10% medium at 37°C in 6% CO<sub>2</sub>, 5% O<sub>2</sub> and 89% N<sub>2</sub> for up to 3 days to the 4–8-cell stage. For M-phase injections, CRISPR-Cas9 was co-injected with sperm during ICSI. A single sperm was first washed in a 4- $\mu$ l drop of mixture containing Cas9 protein, sgRNA, and ssODN as described above.

**Blastomere isolation, whole-genome amplification and Sanger sequencing.** *Zonae pellucidiae* from 4–8-cell stage embryos were removed by brief exposure to acidic Tyrode solution (NaCl 8 mg/ml, KCl 0.2 mg/ml, CaCl<sub>2</sub>·2H<sub>2</sub>O 2.4 mg/ml, MgCl<sub>2</sub>·6H<sub>2</sub>O 0.1 mg/ml, glucose 1 mg/ml, PVP 0.04 mg/ml). *Zona-free* embryos were briefly (30 s) exposed to a trypsin solution (0.15% in EDTA containing Ca- and Mg-free PBS) before manual disaggregation into single blastomeres with a small bore pipette. A total of 830 blastomeres were isolated from 131 embryos, including 19 from control, 54 from zygote-injected and 58 from M-phase-injected groups. Individual blastomeres were transferred into 0.2-ml PCR tubes containing 4  $\mu$ l PBS and placed into a freezer at –80°C until further use. Whole-genome amplification was performed using a REPLI-g Single Cell Kit (Qiagen). Successful amplification was evaluated by PCR for *MYBPC3* and Sanger sequencing. Briefly, amplified DNA was diluted 1/100 and the on-target region for *MYBPC3* was amplified using a PCR Platinum SuperMix High Fidelity Kit (Life Technologies) with primer set: F 5'-CCCCACCCAGGTACATCTT-3' and R 5'-CTAGTGCACAGTGCATAGTG-3'. PCR products of 534 base pairs (bp) were purified, Sanger sequenced and analysed by Sequencher v5.0 (GeneCodes). Of 830 blastomeres, 730 (88%) resulted in successful libraries and produced PCR products for *MYBPC3* while the remaining 100 blastomeres (12%) failed to generate PCR products and were excluded from the study.

**iPSC derivation and transfection with CRISPR-Cas9.** Patient iPSCs were derived from skin fibroblasts with a CytoTune-iPS Reprogramming Kit (Life Technologies), according to the manufacturer's protocol. Cell lines were cultured in mTeSR1 medium (STEMCELL technology) at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. To test CRISPR-Cas9, 2 × 10<sup>5</sup> iPSCs were dissociated into single cells (using Accutase from STEMCELL technology, or TrypLe from Invitrogen). For the CRISPR-Cas9-1 construct (in the J.-S.K. laboratory), Cas9 expression plasmid (p3 s-Cas9HC, 2.4  $\mu$ g), sgRNA expression plasmid (pU6-sgRNA, 1.6  $\mu$ g) and ssODN-1 (100 pmol, IDT) were transfected into iPSCs using an Amaxa P3 Primary Cell 4D-Nucleofector Kit (Program CB-150) according to the manufacturer's protocol. Three days after transfection, ~5,000 cells were plated onto a Matrigel-coated culture dish and cultured for clonal propagation and individual clone selection. For the CRISPR-Cas9-2 construct (in the J.C.I.B. laboratory), Cas9 expression plasmid (pCAG-1BP-NLS-Cas9-1BP-NLS, 15  $\mu$ g), sgRNA expression plasmids (pCAGm-Cherry-MYBPC3gRNA, 15  $\mu$ g) and 30  $\mu$ g ssODN-2 (IDT) were co-transfected by electroporation using the BioRad Gene Pulser II (a single 320-V, 200- $\mu$ F pulse at room temperature) with a 0.4-cm gap cuvette. Cells were plated at high density on 6-well plates coated with Matrigel. Two to three days after electroporation, iPSCs were harvested and subjected to clonal selection. All cell lines were negative for mycoplasma contamination. For direct comparisons of CRISPR-Cas9-1 and CRISPR-Cas9-2, Cas9 RNP complexes, composed of the recombinant Cas9 protein (15  $\mu$ g) and sgRNA (20  $\mu$ g), were co-transfected with ssODN-1 (50–200 pmol, IDT) into iPSCs (2 × 10<sup>5</sup> cells) via electroporation as described above. Three days after transfection, indel and HDR efficiencies were analysed by targeted deep sequencing.



**Recombinant Cas9 protein and *in vitro* transcription of sgRNA.** Recombinant Cas9 protein was purchased from ToolGen, Inc. The sgRNA was synthesized by *in vitro* transcription using T7 polymerase (New England Biolabs) as described previously<sup>45</sup>. In brief, sgRNA templates were generated by annealing and extension of two oligonucleotides (Extended Data Table 1). Then, *in vitro* transcription was performed by incubating sgRNA templates with T7 RNA polymerase supplemented with NTPs (Jena Bioscience) and RNase inhibitor (New England Biolabs) overnight at 37°C. *In vitro* transcribed RNA was then treated with DNase I (New England Biolabs) for 30 min at 37°C, and purified using MinElute Cleanup kit (Qiagen).

**Targeted deep sequencing, genomic DNA cleavage, WGS and Digenome sequencing.** To analyse HDR and NHEJ frequencies, on-target and off-target regions were amplified using Phusion polymerase (New England Biolabs). PCR amplicons were subjected to paired-end sequencing using Illumina Miniseq. Cas-analyzer was used for analysing indel and HDR frequencies<sup>46,47</sup>. The primers used for amplification are listed in Extended Data Table 5. Genomic DNA was isolated from patient iPSCs using a DNeasy Tissue Kit (Qiagen). Digenome-seq was performed as described<sup>25,26</sup>. In brief, 20 µg genomic DNA was cleaved by incubating recombinant Cas9 protein (16.7 µg) and *in vitro* transcribed sgRNA (12.5 µg) in 1 × NEB buffer 3.1 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 100 µg/ml BSA, pH 7.9) at 37°C for 3 h. Cas9- and sgRNA-treated genomic DNA was treated with 50 µg/ml RNase A (Sigma Aldrich) at 37°C for 30 min, and purified with a DNeasy Tissue Kit (Qiagen). WGS and Digenome sequencing were performed as described previously<sup>25,26</sup>. In brief, 1 µg genomic DNA was fragmented and ligated with adaptors using TruSeq DNA libraries. DNA libraries were subjected to WGS using an Illumina HiSeq X Ten Sequencer at Macrogen (30 × to 40 ×). The sequence file was aligned to the human reference genome hg19 from UCSC with the following mapping program and parameters using Isaac aligner<sup>48</sup>: base quality cutoff, 15; keep duplicate reads, yes; variable read length support, yes; realign gaps, no; and adaptor clipping, yes (adaptor: AGATCGGAAGAGC\*, \*GCTCTTCCGATCT). *In vitro* DNA cleavage sites were identified computationally using a DNA cleavage scoring system described previously<sup>26</sup>. Indel frequencies of 23 genomic loci with DNA cleavage score above the 0.1 cutoff value were individually examined in individual blastomeres by targeted deep sequencing. Primers for detecting indel frequencies of Digenome-seq captured sites are listed in Extended Data Table 5.

**Analysis of off-target effects in CRISPR-Cas9-injected human embryos by WGS.** WGS was performed using an Illumina HiSeq X Ten sequencer with a sequencing depth of 30 × to 40 × (Macrogen, South Korea). Sequences from each blastomere were processed to obtain total variants (lane 1 in Extended Data Table 6) using the Isaac variant calling program<sup>48</sup>. Annotated variants, including dbSNPs and all novel SNPs (substitution changes), were filtered out, and novel indel sites were identified (lane 2 in Extended Data Table 6). Cas-OFFinder<sup>46</sup> was used to extract potential off-target sequences that differed from the on-target sequence by up to 7-nucleotide mismatches or up to 5-nucleotide mismatches with a DNA bulge of up to 2 nucleotides. Indel sites found in each blastomere were compared to homologous sites identified by Cas-OFFinder and potential off-target sites were identified (lanes 3 and 6 in Extended Data Table 6). Then, we excluded potential off-target sites, which were found in intact control embryos (C2.3 and C10.2, lanes 4 and 7 in Extended Data Table 6). Finally, we determined whether each of these potential off-target sites was caused by CRISPR-Cas9 by inspecting sequences with Integrative Genomics Viewer<sup>27</sup> (IGV, lanes 5 and 8 in Extended Data Table 6).


**Whole-exome sequencing and data analyses.** Whole-exome sequencing (WES) was performed using genomic DNAs isolated from peripheral blood of the sperm donor and two egg donors (egg donor1 and egg donor2) and ES cells derived from individual human embryos (ES-WT1, ES-Mut1 and ES-C1 were from egg donor1; ES-WT2 and ES-WT3 were from egg donor2). ES-WT1, ES-WT2 and ES-WT3 were from treated wild-type embryos. ES-C1 was from an untreated wild-type embryo. ES-Mut1 was from a treated heterozygous mutant embryo. Sequencing libraries were prepared according to the instructions for Illumina library preparation. Exome capture was done using an Agilent V5 chip. Sequencing was done on an Illumina HiSeq 4000 platform with paired-end 101 (PE101) strategy at a depth of 100 ×. All sequencing data were first processed by filtering adaptor sequences and removing low quality reads or reads with a high percentage of N bases using SOAPnuke (1.5.2) software (<http://soap.genomics.org.cn/>) developed by BGI, and clean reads were generated for each library. Clean data were paired-end aligned using the Burrows-Wheeler Aligner (BWA) program version 0.7.12 to the human genome assembly hg19. Duplicate reads in alignment BAM files were identified using MarkDuplicates in Picard (1.54). The alignment results were processed by RealignerTargetCreator, IndelRealigner and BaseRecalibrator modules in GATK (3.3.0). Variant detection was performed using HaplotypeCaller tool in GATK. SNV and indel information was extracted and filtered by VQSR in GATK and annotated by AnnoDB (v3).

The guide sequence (GGGTGGAGTTTGTGAAGTAT) was aligned to the human genome assembly hg19 to identify potential off-target sites by full sensitive aligner Batmis (V3.00), allowing a maximum of five mismatches globally and a maximum of two mismatches in the core region (12 bp adjacent to the PAM site). Inherited variants from parents and all novel SNPs (substitution changes) were filtered out, and novel indels located within the off-target site plus flanking 20-bp region were defined as off-target variants.

**Statistical analyses.** Student's *t*-test was used for the comparisons in Fig. 4a. One-tailed Fisher's test was used for the comparisons in Fig. 2f, Fig. 3c, and Extended Data Fig. 1e. One-way ANOVA with Bonferroni test was used for the comparisons in Extended Data Table 2. A *P* value less than 0.05 was considered significant. No statistical methods were used to predetermine sample size. The experiments were randomized and the investigators were blinded to allocation during experiments and outcome assessment whenever possible.

**Data availability.** The sequencing data sets, including WGS, WES and Digenome-seq, generated during the current study are not being made publicly available owing to concerns that the data could reveal the research participant's genetic identity, and revealing the identity would be against the participant's wishes and consent. However, the data will be made available to researchers from the corresponding author on reasonable request, dependent upon OHSU IRB approval.

44. Tachibana, M. *et al.* Towards germline gene therapy of inherited mitochondrial diseases. *Nature* **493**, 627–631 (2013).
45. Kim, J. M., Kim, D., Kim, S. & Kim, J. S. Genotyping with CRISPR-Cas-derived RNA-guided endonucleases. *Nat. Commun.* **5**, 3157 (2014).
46. Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. *Bioinformatics* **30**, 1473–1475 (2014).
47. Park, J., Lim, K., Kim, J. S. & Bae, S. Cas-analyzer: an online tool for assessing genome editing results using NGS data. *Bioinformatics* **33**, 286–288 (2017).
48. Raczky, C. *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. *Bioinformatics* **29**, 2041–2043 (2013).




Extended Data Figure 1 | See next page for caption.

**Extended Data Figure 1 | CRISPR–Cas9 design and testing in patient iPSCs.** **a, b**, Schematic of CRISPR–Cas9-1 and CRISPR–Cas9-2 constructs. Both systems consist of a single-chain chimaeric sgRNA designed to target the *MYBPC3*<sup>ΔGAGT</sup> deletion and Cas9 protein. Exogenous single-stranded oligodeoxynucleotide (ssODN) templates encoding homology arms to the targeted region were designed for each system to facilitate HDR. Synonymous single-nucleotide substitutions were introduced into each ssODN template as indicated by red letters. Underline in 1a represents wild-type sequence of 4-bp deletion in the ssODN-1. In addition, the ssODN-2 nucleotide substitutions provide a restriction enzyme (BstBI) recognition site as indicated with black open box. **c**, Patient iPSCs were transfected with CRISPR–Cas9 plasmids by electroporation and individual

single iPSC clones were analysed. **d**, Representative chromatographs showing untargeted iPSC clone with heterozygous mutant (left), targeted iPSC clone with gene corrected via HDR using ssODN-2 as repair template (middle) and targeted iPSC clone with gene corrected via HDR using wild-type sequence as template. **e**, Targeting and HDR efficiency comparison between CRISPR–Cas9-1 and CRISPR–Cas9-2. The asterisk indicates a significantly higher targeting efficiency of CRISPR–Cas9-1 compared to CRISPR–Cas9-2 ( $P < 0.05$ ) by one-tailed Fisher's test. For source data, see Supplementary Table 1. **f**, HDR and NHEJ efficiency in wild-type ES cells (H9) and patient iPSCs transfected with preassembled Cas9 ribonucleoproteins (RNPs).

a



b

Verification of blastomere genotypes by on-target deep sequencing

Treatment	No. of blastomeres or samples	Genotypes by Sanger	Total reads	WT reads (%)	Mutant reads (%)
Intact control WT embryos	8	WT/WT	10007	9993 (99.9%)	14 (0.1%)
Intact control mutant embryos	8	WT/Mut	10281	4988 (48.5%)	5293 (51.5%)
Zygote injection WT embryos	14	WT/WT	13433	13426 (99.9%)	7 (0.1%)
Zygote injection mutant embryos	16	WT/Mut	11583	6942 (59.9%)	4641 (40.1%)
Zygote injection mosaic embryos	8	WT/HDR	13193	13191 (99.99%)	2 (0.01%)
MII injection WT embryos	5	WT/NHEJ	9634	6330 (65.7%)	3304 (34.3%)
MII injection WT embryos	12	WT/WT	12613	12607 (99.9%)	6 (0.1%)
MII injection mutant embryos	15	WT/NHEJ	11016	3969 (36%)	7047 (64%)
Oocyte donor blood	2	WT/WT	10463	10445 (99.8%)	18 (0.2%)

**Extended Data Figure 2 | Differences in DNA repair responses in human embryos and iPSCs and independent validation of on-target genotyping.** **a**, Different HDR-based DNA repair was observed in patient embryos compared to iPSCs. In human embryos, induced DSBs in the mutant paternal gene were repaired exclusively using the wild-type maternal allele as a template. In striking contrast, HDR in iPSCs was directed by the external ssODN-1 template. **b**, Verification of blastomere


on-target genotypes by deep sequencing. DNA samples from 86 individual blastomeres representing different treatments and controls were sequenced using the MiSeq platform. Total reads, wild-type reads and mutant reads are presented as a mean. Distribution of mutant reads in heterozygous (34.3–64%) or homozygous (0.01–0.1%) blastomeres in experimental embryos was similar to controls.

a


Origin and genotypes of ES cells derived from CRISPR-Cas9 injected embryos

ES cell line designation	Treatment	Karyotype	On target genotype	Egg donor
ES-WT1	M-phase injection	46,XX	WT/WT	Egg donor 1
ES-WT2	M-phase injection	46,XX, inv(10)(p11.2q21.2)	WT/WT	Egg donor 2
ES-WT3	M-phase injection	46,XY, inv(10)(p11.2q21.2)	WT/WT	Egg donor 2
ES-WT4	M-phase injection	46,XX	WT/WT	Egg donor 2
ES-Mut1	M-phase injection	46,XX	WT/NHEJ	Egg donor 1
ES-Mut2	M-phase injection	46,XX	WT/NHEJ	Egg donor 2
ES-C1	Intact control	46,XY, inv(10)(p11.2q21.2)	WT/WT	Egg donor 1


b

ES-WT3  
46,XY, inv(10)(p11.2q21.2)

c


Chromosome 10  
inv(10)(p11.2q21.2)

d


Chromosome 10  
ideograms

**Extended Data Figure 3 | Genetic stability of ES cells derived from CRISPR-Cas9-injected embryos.** **a**, Origin and genotypes of ES cells derived from CRISPR-Cas9-injected embryos. **b**, Karyotype of ES-WT3 showing a pericentric inversion on chromosome 10. **c**, Magnified image

showing normal (left chromosome) and inverted chromosome 10 (right chromosome, inverted region indicated by arrow). **d**, Chromosome 10 ideogram showing the location of the inversion.




**Extended Data Figure 4 | Digenome sequencing of potential off-target sites. a**, Representative Integrative Genomics Viewer (IGV) images produced using CRISPR-Cas9 at the on-target site. **b**, Representative IGV images showing CRISPR-Cas9-induced DNA cleavage at the potential off-target sites. Red arrows indicate DNA cleavage sites at each off-target site.




**Extended Data Figure 5 | Digenome-seq based off-target mutation screening of treated human embryos.** **a**, Genome-wide Circos plots showing DNA cleavage scores. Cas9-only-treated DNA is shown in grey, and CRISPR-Cas9-treated DNA is in blue. **b**, Sequence logo obtained via WebLogo using Digenome-captured sites (DNA cleavage score >2.5). On-target sequence is indicated below the sequence logo. PAM sequence is shown in blue. **c**, On-target indels for 28 blastomeres detected by Digenome-seq. Only blastomeres carrying NHEJ were captured by

Digenome-seq. Blastomeres indicated in red fonts were also analysed by WGS (Extended Data Table 6). **d**, Indel frequencies for potential off-target sites captured by Digenome-seq in CRISPR-Cas9-treated ( $n = 5$ ) and untreated control embryos ( $n = 2$ ). Mismatch nucleotides are shown in red. PAM sequence is shown in blue. OnT: on target site; OT: off-target. Percentages of mutagenic indels on the  $x$ -axis are presented on a logarithmic scale. For source data, see Supplementary Table 5.


a



b



c



**Extended Data Figure 6 | WES analysis of ES cell lines derived from CRISPR-Cas9-injected embryos. a,** SNP and indel fractions of variants identified in each sample presented in dbSNP and 1000genomes databases. **b,** Numbers of coding region variants (SNPs) in each sample divided into

indicated categories. **c,** Numbers of coding region variants (indels) divided into indicated categories. Hg19 was used as a reference genome for variant calling. Data presented as mean with interquartile range (black horizontal bars). For source data, see Supplementary Tables 6–8.



**Extended Data Table 1 | DNA oligo sequences used for CRISPR–Cas9-based gene correction**

CRISPR-Cas9-1	Guide oligo for cloning of sgRNA (19bp)- encoding plasmid	Forward	CACCGGGTGGAGTTTGTGAAGTAT
		Reverse	AAACATACTTCACAACTCCACCC
	<i>In vitro</i> transcription templates for encoding sgRNA	Forward	GAAATTAATACGACTCACTATAGGTGGAGTTTGTGAAGTATGTTTTAGAGCTAGAAATAGCA AG
		Reverse	AAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTAACT TGCTATTTCTAGCTCTAAAAC
	Single-stranded oligonucleotide (ssODN-1)	200 mer	AGATGGCCTCAGGGGAGCCAACCCTCATGCTCACCTGCCTGGACAGAGCCCCCTGTGC TCATCAGCGCCCTTGGAGGACCAGCTGGTGTGGTGGGGCAGCGGGTGGAGTTGA GTGCGAGGTATCGGAGGAGGGGGCGCAAGTCAAATGGTGGTTCAGAAAGCACGGGGC ATGGGTGTTGGGGGCATCTGCCAG
	CRISPR-Cas9-2	Guide oligo for cloning of sgRNA (20bp) - encoding plasmid	Forward
Reverse			GCCTTATTTAACTTGCTATTTCTAGCTCTAAAACATACTTCACAACTCCACCC
Single-stranded oligonucleotide (ssODN-2)		100 mer	CTTCTGGAACACCATTTGACTTGCGCCCTCCTCCGATACTTCACATTCGA <u>ACTCCA</u> CCCGCTGCCCCACCATCACCAGCTGGTCTCCAAGGGGCG

Note: Bold letters in ssODN-1 represent synonymous nucleotide substitutions. Underlined and bold letters in ssODN-2 represent restriction enzyme (BstBI) recognition site and synonymous substitutions, respectively.

Extended Data Table 2 | Preimplantation development of human oocytes and zygotes after CRISPR-Cas9 injection

Group	No. of oocytes	Survived after CRISPR-Cas9 injection	Fertilized	4-8-cells
Intact control	22	N/A	21/22 (95.5%)	19/22 (86.4%)
Zygote injection	70	68/70 (97.1%)	58/70 (82.9%)	54/70 (77.1%)
MII injection	75	73/75 (97.3%)	63/75 (84.0%)	58/75 (77.3%)

N/A, not applicable.

Extended Data Table 3 | Genotypes of blastomeres in mosaic human embryos produced by CRISPR-Cas9 injection into zygotes

Embryo ID	Treatment	No. of Blastomeres	Maternal <i>MYBPC3</i> allele	Paternal <i>MYBPC3</i> allele				
			Intact WT	Intact mutant	HDR via WT allele	NHEJ	Indels	No. of genotypes
<b>Mos1</b>	CRISPR-Cas9+ssODN	8	8	0	6	2	5 bp deletion (n=2)	2
<b>Mos2</b>	CRISPR-Cas9+ssODN	3	3	0	2	1	1 bp insertion (n=1)	2
<b>Mos3</b>	CRISPR-Cas9+ssODN	6	6	0	1	5	3 bp deletion (n=5)	2
<b>Mos4</b>	CRISPR-Cas9+ssODN	4	4	0	3	1	1 bp insertion (n=1)	2
<b>Mos5</b>	CRISPR-Cas9+ssODN	7	7	3	2	2	12 bp deletion (n=2)	3
<b>Mos6</b>	CRISPR-Cas9 alone	3	3	0	2	1	17 bp deletion (n=1)	2
<b>Mos7</b>	CRISPR-Cas9 alone	4	4	0	3	1	5 bp deletion (n=1)	2
<b>Mos8</b>	CRISPR-Cas9 alone	4	4	2	2	0	NA	2
<b>Mos9</b>	CRISPR-Cas9 alone	5	5	0	0	5	1 bp deletion (n=3) 20 bp deletion (n=1) 10 bp deletion+5 bp insertion (n=1)	4
<b>Mos10</b>	CRISPR-Cas9 alone	6	6	2	4	0	NA	2
<b>Mos11</b>	CRISPR-Cas9 alone	3	3	0	2	1	7 bp deletion (n=1)	2
<b>Mos12</b>	CRISPR-Cas9 alone	8	8	0	7	1	1 bp insertion (n=1)	2
<b>Mos13</b>	CRISPR-Cas9 alone	6	6	5	1	0	NA	2

Extended Data Table 4 | List of potential off-target sites captured by Digenome-seq

Gene	No.	Target sequence	Genomic position	DNA cleavage score	Direction
MYBPC3	OnT	GGTGGAGTTT----GTGAAGTATCGG	chr11:47342852-47342877	58.33	-
NR6A1	OT1	GATGAAGTTTGTGGAGTATGGG	chr9:124675081-124675102	62.78	-
NAA16	OT2	GGAAAGAGTTTGTGAAGAATTGG	chr13:41348697-41348718	62.21	+
intergenic	OT3	TGTGGAGTTGGTGAAGTATTGG	chr5:25071527-25071548	61.63	+
DECR1	OT4	TGTGGAGTTGGTGAAGTATGGG	chr8:90005165-90005183	52.32	+
AUTS2	OT5	CTTGGAGTTTGTGAAGTCTGGG	chr7:69788454-69788475	46.09	+
MPP6	OT6	GAAAGAGTTTGTGAAGTATTGG	chr7:24623217-24623238	38.03	+
RP11-718G2.5	OT7	GGAGGTGTTTATGAAGTATAGG	chr14:70282053-70282074	28.22	-
CDS2	OT8	GGCAGAGTTTGTGAAGTCTAGG	chr20:5194679-5194700	28.09	+
SHROOM4	OT9	GGGAGAGTTTGTGAAGTATTGG	chrX:50758717-50758738	26.88	+
intergenic	OT10	AGTAGAGTTTGTGAAGAATTGG	chr2:6707127-6707148	17.72	-
XRRA1	OT11	GGAAAGAGTTTGTGAAGTATTGG	chr11:74846389-74846410	14.67	-
intergenic	OT12	GGAAAGAGTTTGTGAAGTATTGG	chr4:95671059-95671080	13.96	+
intergenic	OT13	GGAAAGAGTTTGTGAAGGATTGG	chr10:43950064-43950085	9.91	+
intergenic	OT14	TGTGAAGTTTGTGAAGAATTGG	chr14:28679702-28679723	8.27	+
MRPS22	OT15	AGAAAGAGTTTGTGAAGTATTGG	chr3:139269115-139269136	4.42	+
intergenic	OT16	AGGTGGAGATGTGGAGTATGGG	chr14:69816965-69816986	3.38	+
intergenic	OT17	GGAAAGAGTTAGTAAAGTATAGG	chrX:19292291-19292312	1	+
HS6ST3	OT18	GGTAAAGTTTCTGAAGTATGGG	chr13:96768853-96768874	0.56	-
SLC36A2	OT19	GGAAAGAGATGTGAAGTATGGG	chr5:151344278-151344299	0.42	+
TTC7B	OT20	GGAGGAGTTTGTGAAGAATTGG	chr14:90762986-90763007	0.28	-
intergenic	OT21	GAAAGAGTTTGTGAAGTATTGG	chr2:10508207-10508228	0.23	-
intergenic	OT22	GGGGAAGTTGTAAAGTATTGG	chr12:87612131-87612152	0.16	+
RPS14	OT23	GGAGGAGCTTGTGAAGTAAGGG	chr5:150449485-150449506	0.16	-

OnT, on-target; OT, off-target; captured by Digenome sequencing. Red letters indicate mismatched nucleotides.

Extended Data Table 5 | List of PCR primers used in targeted deep sequencing

No.	1 <sup>st</sup> PCR		2 <sup>nd</sup> PCR	
	Forward (5' ->3')	Reverse (5' ->3')	Forward (5' ->3')	Reverse (5' ->3')
OnT	CCCACCCAGGTACATC TTTG	TGATCAGGTGGTGTCT CTGC	ACACTCTTTCCCTACACGACGCTCTCCGATCTACCT GAGGATGTGGGAACCT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCAA GTGCTGTGGCCCTTCT
OT1	CAGCAACATAAGCCA GTCCA	AAGAGAGGCCCAATG GAAAT	ACACTCTTTCCCTACACGACGCTCTCCGATCTCAG CAACATAAGCCAGTCCA	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTAG AAATGCCTTCTCGCTTA
OT2	CAGGGTGATACTGGC CTCAT	AACCCAAAACCTGGCT CTTT	ACACTCTTTCCCTACACGACGCTCTCCGATCTCAG GGTGATACTGGCCTCAT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTGTC CAGGCCATATGACTTC
OT3	TGTGAGGCAGAATCC TTTGA	CACAGGCATATGAAAC ACTGG	ACACTCTTTCCCTACACGACGCTCTCCGATCTTCA AAGTGTGAGGCAGAATCC	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCCC TCTATCAAGCTGCTATCTCA
OT4	AAAGCTTCATGGAGG AGGTG	GATCCATCCAAAAGC AAGA	ACACTCTTTCCCTACACGACGCTCTCCGATCTGGA ATTTGTGTGGTCCCAAT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTAA GAAAAGCCACCATACCC
OT5	CCCTATGAAAGAGGG TGCAA	GCTGAACCCGACAGCT AATC	ACACTCTTTCCCTACACGACGCTCTCCGATCTATA GAGGCTCAGGGGAAGG	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTACC AAGTCCCTCAGGTTA
OT6	CACTCGTTCATTCTG GGATA	ACAACCTTGCACTTGCT CTG	ACACTCTTTCCCTACACGACGCTCTCCGATCTTTTT TGTGTGATGTTGTTGG	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTACC AGCCTTCACTAGGAAT
OT7	GCAGACATCTACGGC AGACA	TGTGAGTGAGGCCACCA GAAG	ACACTCTTTCCCTACACGACGCTCTCCGATCTCAG CTGGGGCTTAAACAAGAG	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCAC CCCAACTTGTTCATCTCA
OT8	CTTCCCTTTCAGGTG ACCA	GCTCTCGGCCTCAGTC ATAC	ACACTCTTTCCCTACACGACGCTCTCCGATCTTTTC CCAACGCATTTGGTATG	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTGC ATTTGATGGAAAAGGAA
OT9	CAGCCTTGCACTTCTA AGGT	TCAAGAATTGAGGAGG GAACA	ACACTCTTTCCCTACACGACGCTCTCCGATCTTCCA CTTGGTCATGGCCTAT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTAG CCCAGGTCAAAAGAGTTT
OT10	TGCCTTATTTCTGCTCT CAGG	CAGATGGCTTCAGCAC TTCA	ACACTCTTTCCCTACACGACGCTCTCCGATCTCTTC CCTTGGTCATGGTGT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCA GATGGCTTCAGACTTCA
OT11	CCAGATGTTAAACCAA CCTTTCA	AGCCTGGGCAACATAG TGAG	ACACTCTTTCCCTACACGACGCTCTCCGATCTTTTT TCCTTCTTGTGATGCTTTTC	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCAA AGAAAAGCCAAGGACCA
OT12	ATCCAGTTGGTCATG GTGT	TGCCAACAATTAGACA AAAACA	ACACTCTTTCCCTACACGACGCTCTCCGATCTTTGT TTCTGGATTGGTTTCC	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTTCC CAGGCCACAGATAGATAG
OT13	TCGGAATGCACATCTC TGTC	GCTCAGATAGCCTCAA AGGTG	ACACTCTTTCCCTACACGACGCTCTCCGATCTTTTT CTGGATTGGTTTGTCT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTGCT CAGATAGCCTCAAAGGTG
OT14	AAAGGGGAAAAAGG TGAAAA	CCAGGTCCAGATGCCT TACT	ACACTCTTTCCCTACACGACGCTCTCCGATCTTGT GAGAGATTTGGTCTGTGA	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCCA GGTCCAGATGCCTTACT
OT15	CTGGCCTTCTGGGAT AAAT	AGGTGAAATGGACAAA TTCT	ACACTCTTTCCCTACACGACGCTCTCCGATCTCAG GGTAATTTGGCCTCAG	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTAAC TTCCCAAGGAAATGC
OT16	GCAAGAAAGGCTTGG ATCTG	GTCTCCAGGTGGTTTT TCA	ACACTCTTTCCCTACACGACGCTCTCCGATCTCAG GGGTAAAGGAGGGAGAG	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTACC CAAACGCTGATGACTTC
OT17	GCAAGAGCTAGCTGC ACGAT	TTGGACAGGCTGAAA TAGG	ACACTCTTTCCCTACACGACGCTCTCCGATCTGGC ACAAAAGAGGCTATGCT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTAG GCAGAAGCCAGAACAGTC
OT18	TGCCCTGTTGAAATGA ACCT	TTCTTCTGCCACGTA AAC	ACACTCTTTCCCTACACGACGCTCTCCGATCTCTG GAACAATGATCGGGTCT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTGC CGTTTAGTCTGCTTGTCT
OT19	AACCCTAGAGCCTCT CCTC	AGGGGTGAAGAACAG GGACT	ACACTCTTTCCCTACACGACGCTCTCCGATCTCTTC ACAGCCAGGGGTATGC	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTTG GGATGGTTGGTAAACCTA
OT20	AAACCAACCTTGCACT CCTG	CGCCTGAAACTGGGAA ATAA	ACACTCTTTCCCTACACGACGCTCTCCGATCTTGT CCCTCTTTTCTGCTT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTGC CATGACCAAGAGGCTAAG
OT21	TCCTGTGTCTGTTGGG ATGA	GAGACAGGGTTTTGCC ATGT	ACACTCTTTCCCTACACGACGCTCTCCGATCTTGT AGCATTTTGTGGAGGA	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTAG GCCCAGATAGCTTCACTG
OT22	TTGCATGAGTGCCATG ACTT	CCTTCCGATATCAGG TTTG	ACACTCTTTCCCTACACGACGCTCTCCGATCTAGA ATGCACAATCCACATGA	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTTG AATCTGAATCCCTGCAT
OT23	CCCTCCACTCTCTCT TCC	TCCTGCTTTCTCTTT GA	ACACTCTTTCCCTACACGACGCTCTCCGATCTCAA CTCGGGATTGAGTTCGT	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCTA CGCTGTGCAGCTCAAAC

OnT, on-target; OT, off-target; captured by Digenome sequencing.

Extended Data Table 6 | Analysis of off-target effects in CRISPR-Cas9-injected human embryos by WGS

		Human embryo blastomere						
Analysis		C2.3	C10.2	Mos1.1	W15.4	Mos7.2	M2-WT10.1	M2-Mut7.1
		Control WT embryo	Control mutant embryo	Zygote injected with ssODN	Zygote injected without ssODN	Zygote injected without ssODN	MII injected with ssODN	MII injected without ssODN
Lane1	No. of total variants	1604350	2348616	3188787	2024463	2506788	2730525	1935404
Lane2	No. of indels after excluding dbSNPs	90481	91073	81037	51146	43827	41016	31267
PAM-containing homologous sites with up to 5 nucleotide mismatches + a DNA bulge of up to 2 nucleotides (465004)								
Lane3	No. of potential off-target sites	14	14	6	12	8	15	3
Lane4	No. of potential off-target sites excluding sites found in C2.3 or C10.2	N/A	N/A	4	9	6	11	3
Lane5	No. of off-target sites	N/A	N/A	0	0	0	0	0
PAM-containing homologous sites with up to 7 nucleotide mismatches (476552)								
Lane6	No. of potential off-target sites	68	64	41	30	44	76	19
Lane7	No. of potential off-target sites excluding sites found in C2.3 or C10.2	N/A	N/A	32	24	35	60	16
Lane8	No. of off-target sites	N/A	N/A	0	0	0	0	0

Lane 1: total number of variants including SNPs and small indels. Lane 2: number of indel sites in the human embryo blastomeres excluding dbSNPs. Lanes 3 and 6: number of potential off-target sites whose sequences are homologous with the on-target sequence. Lanes 4 and 7: number of potential off-target sites found in CRISPR-Cas9-injected embryos excluding those found in intact control embryos (C2.3 or C10.2). Lanes 5 and 8: number of off-target sites excluding repeated sequences such as poly-A repeats or poly-GT repeats. N/A, not applicable.

## Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work we publish. This form is published with all life science papers and is intended to promote consistency and transparency in reporting. All life sciences submissions use this form; while some list items might not apply to an individual manuscript, all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### ▶ Experimental design

#### 1. Sample size

Describe how sample size was determined.

We used a minimum number of human oocytes/embryos required for statistical comparisons

#### 2. Data exclusions

Describe any data exclusions.

no data were excluded

#### 3. Replication

Describe whether the experimental findings were reliably reproduced.

Human embryo HDR and mosaicism findings were reproduced with multiple oocyte donations from different donors. All genotyping by Sanger were validated by deep sequencing (MiSeq) independently but two different teams.

#### 4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

Mutant and WT sperm from the heterozygous carrier was randomly picked up and injected into oocytes. CRISPR/Cas9 injection into zygotes or MII oocytes was randomized with controls

#### 5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

During all on-target and off-target sequencing, the personnel was blinded regarding the sample origin

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

#### 6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).

- |                                     |  |
|-------------------------------------|--|
| n/a                                 | Confirmed  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The <u>exact</u> sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)                                    |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement indicating how many times each experiment was replicated   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section) |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of any assumptions or corrections, such as an adjustment for multiple comparisons   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The test results (e.g. $p$ values) given as exact values whenever possible and with confidence intervals noted   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Clearly defined error bars   |

See the web collection on [statistics for biologists](#) for further resources and guidance.

## ► Software

Policy information about [availability of computer code](#)

### 7. Software

Describe the software used to analyze the data in this study.

We described all software used for sequence analyses in the method section.

For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The *Nature Methods* [guidance for providing algorithms and software for publication](#) may be useful for any submission.

## ► Materials and reagents

Policy information about [availability of materials](#)

### 8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

CRISPR/Cas9, ESCs and iPSCs from this study are available for distribution following MTA

### 9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

N/A

### 10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

All ESC and iPSC lines included in the study were generated in this study

b. Describe the method of cell line authentication used.

WGS, WES and Sanger sequencing, karyotyping

c. Report whether the cell lines were tested for mycoplasma contamination.

Yes, all cell lines were tested for mycoplasma contamination and were negative

d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

None

## ► Animals and human research participants

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

### 11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

N/A

Policy information about [studies involving human research participants](#)

### 12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

Provided in detail in the material and method section